High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells

Novel agents such as the Bcl-2 inhibitor venetoclax (ABT-199) are changing treatment paradigms for chronic lymphocytic leukemia (CLL) but important problems remain. Although some patients exhibit deep and durable responses to venetoclax as a single agent, other patients harbor subpopulations of resi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Oppermann, Sina, Ylanko, Jarkko, Shi, Yonghong, Hariharan, Santosh, Oakes, Christopher C., Brauer, Patrick M., Zúñiga-Pflücker, Juan C., Leber, Brian, Spaner, David E., Andrews, David W.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2016
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5000578/
https://ncbi.nlm.nih.gov/pubmed/27297795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-12-687814
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky